TMCnet News

Webcast Alert: Scott Mize to be Keynote Speaker for Trilogy Capital's Online Nanotechnology Forum
[May 04, 2004]

Webcast Alert: Scott Mize to be Keynote Speaker for Trilogy Capital's Online Nanotechnology Forum

LOS ANGELES --(Business Wire)-- May 4, 2004 -- Friday, May 7 Webcast Focusing on Emerging Nanotechnology Companies and Developments

Trilogy Capital Partners announced today that Scott Mize, founder of AngstroVision, Inc., an early stage company focused on creating a breakthrough nano-imaging device, will deliver the keynote presentation for Trilogy's Online Nanotechnology Forum to be webcast on Friday, May 7, at 12:00 pm EDT. The presenting companies for the forum are Biophan Technologies, Inc. (OTC BB: BIPH), Isonics Corporation (NASDAQ: ISON), MFIC Corporation (OTC BB: MFIC) and Molecular Imaging Corporation (OTC BB: MLRI).

Mr. Mize will discuss the recent developments in the nanotechnology business community and opportunities for investors to participate in this exciting field.

A.J. Cervantes, president of conference sponsor Trilogy Capital Partners, stated, "There are few business professionals who have the deep experience and exceptional insight in the nanotech space that Scott does. In a field that is just burgeoning in the eyes of investors, Scott has been tracking for over 15 years. He is extremely knowledgeable about business developments and investments in this opportunity-rich market. We are very excited to have such a seasoned entrepreneur, advisor and sought-after speaker as Scott be a part of our conference which is designed to present what we believe to be four exceptional opportunities in a fast moving, thirty minute format."

The Online Nanotechnology Forum will be broadcast live over the Internet. Pre-registration is required at

For those unable to participate during the live webcast, the Forum will be archived for replay at

Forum Presenters

Biophan Technologies, Inc. (OTC BB: BIPH). Committed to growth through innovation and developmental leadership, Biophan and its licensors have nine issued U.S. patents and over fifty patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit

Isonics Corporation (NASDAQ: ISON) is divided into two segments: (1) Isonics Semiconductor and (2) Isonics Life Sciences. Isonics is a world leader in isotopically engineered materials and through its semiconductor division produces isotopically pure silicon-28 chemicals and wafers for the semiconductor industry. For more information:

MFIC Corporation (OTC BB: MFIC), through its Microfluidics Division, provides patented and proprietary, high performance Microfluidizer(R) materials processing equipment to the pharmaceutical, biotechnology, chemical, cosmetic/personal care, and food processing industries. To find out more about MFIC, visit its website at

Molecular Imaging Corporation (OTC BB: MLRI) is a leading national service provider of Positron Emission Tomography ("PET") diagnostic imaging services. The Company operates both mobile and permanent (fixed) PET imaging technologies for hospitals, diagnostic imaging centers and physician group practices offices across the U.S.

About Trilogy Capital Partners

Trilogy Capital Partners is a Los Angeles-based financial services company engaged in merchant banking, strategic planning, financial marketing and communications. Based on the simple concept that many well-run public companies are not realizing their full value in the marketplace, Trilogy has aggregated highly experienced executives into a formidable financial and marketing team, which help investors identify and maximize prospective high-return opportunities. Trilogy is committed to identifying companies with strong management, a compelling business model and, most importantly, companies that may be seriously undervalued. For more information on Trilogy, or its portfolio clients, please visit

[ Back To's Homepage ]